202 related articles for article (PubMed ID: 30352887)
1. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
Kiltz U; Kiefer D; Braun J; Schiffrin EJ; Girard-Guyonvarc'h C; Gabay C
Ann Rheum Dis; 2020 Jan; 79(1):e10. PubMed ID: 30352887
[No Abstract] [Full Text] [Related]
2. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
Gabay C; Fautrel B; Rech J; Spertini F; Feist E; Kötter I; Hachulla E; Morel J; Schaeverbeke T; Hamidou MA; Martin T; Hellmich B; Lamprecht P; Schulze-Koops H; Courvoisier DS; Sleight A; Schiffrin EJ
Ann Rheum Dis; 2018 Jun; 77(6):840-847. PubMed ID: 29472362
[TBL] [Abstract][Full Text] [Related]
3. Biological agents in the management of adult-onset Still's disease.
Girard-Guyonvarc'h C; Gabay C
Joint Bone Spine; 2019 Jan; 86(1):5-7. PubMed ID: 29631071
[No Abstract] [Full Text] [Related]
4. Tocilizumab for multirefractory adult-onset Still's disease.
De Bandt M; Saint-Marcoux B
Ann Rheum Dis; 2009 Jan; 68(1):153-4. PubMed ID: 19088261
[No Abstract] [Full Text] [Related]
5. Anti-Golgi antibodies in adult Still's disease.
Staub HL; Souza F; Chan EK; von Mühlen CA
Clin Exp Rheumatol; 2003; 21(2):275-6. PubMed ID: 12747298
[No Abstract] [Full Text] [Related]
6. Transient impairment of NK cell function in an infant born to a mother with adult-onset Still's disease: perinatal effect of maternal IL-18.
Shimizu M; Sakakibara Y; Kawano M; Yachie A
Clin Immunol; 2012 Jun; 143(3):273-4. PubMed ID: 22572478
[No Abstract] [Full Text] [Related]
7. Long-term safety of tocilizumab treatment on chronic active hepatitis C in a patient with adult onset Still's disease.
Forestier E; Pasquali JL
Joint Bone Spine; 2015 Mar; 82(2):136-7. PubMed ID: 25553837
[No Abstract] [Full Text] [Related]
8. Successful treatment with tacrolimus of refractory adult-onset Still's disease.
Ohe M; Oku K; Kono M; Bohgaki T
Korean J Intern Med; 2014 Mar; 29(2):259-61. PubMed ID: 24648814
[No Abstract] [Full Text] [Related]
9. Interleukin-18 in adult-onset Still's disease: treatment target or disease activity indicator?
Nagashima T; Iwamoto M; Matsumoto K; Minota S
Intern Med; 2012; 51(4):449; author reply 451. PubMed ID: 22333388
[No Abstract] [Full Text] [Related]
10. IL-1 Trap rilonacept in refractory adult onset Still's disease.
Petryna O; Cush JJ; Efthimiou P
Ann Rheum Dis; 2012 Dec; 71(12):2056-7. PubMed ID: 22679302
[No Abstract] [Full Text] [Related]
11. Antiproteinase 3 antibody in adult-onset Still's disease.
Al Attia HM
Clin Exp Rheumatol; 2006; 24(1):109-10. PubMed ID: 16539829
[No Abstract] [Full Text] [Related]
12. Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab.
Yamada H; Kaneko Y; Tamai H; Takeuchi T
Rheumatology (Oxford); 2020 Feb; 59(2):440-442. PubMed ID: 31504968
[No Abstract] [Full Text] [Related]
13. Efficacy of thalidomide in refractory adult Still's disease: a new case report.
Meaux-Ruault N; Magy N; Gil H; Dupond JL
Clin Exp Rheumatol; 2003; 21(2):272. PubMed ID: 12747295
[No Abstract] [Full Text] [Related]
14. Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases.
Andrade-Ortega L; Irazoque-Palazuelos F; Muñoz-López S; Rosales-Don Pablo VM
Reumatol Clin; 2014; 10(3):199-200. PubMed ID: 24076178
[No Abstract] [Full Text] [Related]
15. [Adult onset Still's disease with small vessel vasculitis].
Hoff P; Hoyer BF; Schneider U; Kneitz C; Burmester GR; Buttgereit F
Z Rheumatol; 2015 Aug; 74(6):540-2. PubMed ID: 26231832
[TBL] [Abstract][Full Text] [Related]
16. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.
Perdan-Pirkmajer K; Praprotnik S; Tomšič M
Clin Rheumatol; 2010 Dec; 29(12):1465-7. PubMed ID: 20734215
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y; Kameda H; Ikeda K; Ishii T; Murakami K; Takamatsu H; Tanaka Y; Abe T; Takeuchi T
Ann Rheum Dis; 2018 Dec; 77(12):1720-1729. PubMed ID: 30279267
[TBL] [Abstract][Full Text] [Related]
18. [The prognosis and treatment of Still's disease in adults].
Holgado S; Casado E; Olivé A; Tena X
Med Clin (Barc); 1999 Mar; 112(9):356. PubMed ID: 10220769
[No Abstract] [Full Text] [Related]
19. [Tocilizumab effectiveness in adult Still's disease].
López Buitrago R; Estrada Dorronsoro S; Cervera Segura R; Espinosa Garriga G
Med Clin (Barc); 2012 Jan; 138(1):42-3. PubMed ID: 21605875
[No Abstract] [Full Text] [Related]
20. Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent.
Simeni Njonnou SR; Soyfoo MS; Vandergheynst FA
Rheumatology (Oxford); 2019 Oct; 58(10):1878-1879. PubMed ID: 31056689
[No Abstract] [Full Text] [Related]
[Next] [New Search]
